Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jesspro who wrote (4448)	1/9/2017 12:30:32 PM
From: tktom	Respond to of 4474

Fair price? They overpaid based on the PV!!. In three more years, who knows? Congratulations to all that held to the end. Dr. Denner got the job done..

To: jesspro who wrote (4448)	1/9/2017 10:04:52 PM
From: jaybe	5 Recommendations Recommended By ghmm mulanoon2007 rkrw tktom xr1 Read Replies (1) \| Respond to of 4474

I think its fair, but of course I hoped for more, or at least addl. CVRs for '788. However, if '788 turns out to be a dud and the immunokinase platform and TKIs were just window dressing, then its actually a good deal. Only time will tell, it will all get lost in the noise at Takeda. I did have a hunch in late Q4 when they delayed moving into already completed HQ, and of course the pona price increases all make sense now. Its been a rough and wild ride for me since 2004, but all has ended well. Time to scour the pipelines of others for another big adventure.